Global Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) Pipeline Insights Report 2016 Featuring OncoMed, MedImmune & AbbVie - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Pipeline Insights, 2016" report to their offering.

Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4)-Pipeline Insights, 2016 provides comprehensive insights about pipeline drugs across this indication. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4).

This report provides information on the therapeutic development based on the Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) dealing with all the pipeline drugs, comparative analysis of Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

The report also covers the company's information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Reports Highlights:

- Delta-like ligand 4 Therapy Pipeline scenario

- Collaborations & partnering deals

- Current Prominent Research Areas and Key Players

- Pipeline product profiles Delta-like ligand 4Technologies and Targeted Antigens

- Licensing opportunities

- Market Drivers and Barriers

Key Topics Covered:

  1. Overview
  2. Technical Analysis
  3. Pipeline Therapeutics
  4. Therapeutics under Development by Companies
  5. Mid Stage Products (Phase II)
  6. Comparative Analysis
  7. Early Stage Products (Phase I)
  8. Comparative Analysis
  9. Therapeutic Assessment
  10. Assessment by Monotherapy Products
  11. Assessment by Route of Administration
  12. Assessment by Stage and Route of Administration
  13. Assessment by Molecule Type
  14. Assessment by Stage and Molecule Type
  15. Dormant Products
  16. Comparative Analysis
  17. Companies involved in Therapeutics Development
  18. Appendix

Companies Mentioned

- OncoMed

- MedImmune

- AbbVie

For more information visit http://www.researchandmarkets.com/research/f66226/deltalike_ligand

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals